ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice

Journal of the American Academy of Dermatology

Volumn 74, Issue 6, 2016, Pages 1066-1072

  Vilarrasa, Eva ^a   Notario, Jaume ^b   Bordas, Xavier ^b   López Ferrer, Anna ^a   Gich, Ignasi J ^a   Puig, Lluís ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

adalimumab; biologics: cohort; efficacy; etanercept; infliximab; psoriasis; real life; survival; treatment; ustekinumab

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; USTEKINUMAB; BIOLOGICAL PRODUCT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BIOLOGICAL THERAPY; BODY MASS; CHRONIC DISEASE; CLINICAL PRACTICE; COHORT ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MEDICATION COMPLIANCE; OBESITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIASIS VULGARIS; RETROSPECTIVE STUDY; SPAIN; TREATMENT RESPONSE; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; KAPLAN MEIER METHOD; MULTICENTER STUDY; PATIENT COMPLIANCE; PROCEDURES; PROPORTIONAL HAZARDS MODEL; PSORIASIS; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; TIME FACTOR;

ADALIMUMAB; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL PRODUCTS; BIOLOGICAL THERAPY; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLIXIMAB; KAPLAN-MEIER ESTIMATE; MALE; MEDICATION ADHERENCE; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT COMPLIANCE; PROPORTIONAL HAZARDS MODELS; PSORIASIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SPAIN; TIME FACTORS; USTEKINUMAB;

EID: 84962497612     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2016.01.037     Document Type: Article

References (15)

1. A. López-Ferrer, E. Vilarrasa, I.J. Gich, and L. Puig Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish center Br J Dermatol 169 5 2013 1141 1147
2. L. Puig, J.M. Carrascosa, E. Daudén, et al. Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología Spanish evidence-based guidelines on the treatment of moderate-to-severe psoriasis with biologic agents [in Spanish] Actas Dermosifiliogr 100 2009 386 413
3. L. Puig, J.M. Carrascosa, G. Carretero, et al. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment Actas Dermosifiliogr 104 2013 694 709
4. A. Svedbom, J. Dalén, C. Mamolo, J.C. Cappelleri, I.F. Petersson, and M. Ståhle Treatment patterns with topicals, traditional systemics and biologics in psoriasis-a Swedish database analysis J Eur Acad Dermatol Venereol 29 2015 215 223
5. J.M. van den Reek, J. Zweegers, W. Kievit, and et al. 'Happy' drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network Br J Dermatol 171 5 2014 1189 1196
6. Y. Umezawa, Y. Nobeyama, M. Hayashi, and et al. Drug survival rates in patients with psoriasis after treatment with biologics J Dermatol 40 12 2013 1008 1013
7. A.M. Brunasso, M. Puntoni, and C. Massone Drug survival rates of biologic treatments in patients with psoriasis vulgaris Br J Dermatol 166 2 2012 447 449
8. V. Di Lernia, L. Tasin, R. Pellicano, G. Zumiani, and G. Albertini Impact of body mass index on retention rates of anti-TNF-alfa drugs in daily practice for psoriasis J Dermatolog Treat 23 6 2012 404 409
9. M. Esposito, P. Gisondi, N. Cassano, and et al. Survival rate of antitumor necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicenter observational study Br J Dermatol 169 3 2013 666 672
10. R. Gniadecki, K. Kragballe, T.N. Dam, and L. Skov Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris Br J Dermatol 164 5 2011 1091 1096
11. C.R. Mehren, and R. Gniadecki Dose-creep of infliximab during psoriasis treatment: an observational study Acta Derm Venereol 92 4 2012 355 357
12. R. Gniadecki, B. Bang, L.E. Bryld, L. Iversen, S. Lasthein, and L. Skov Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris Br J Dermatol 172 1 2015 244 252
13. S.P. Menting, A.S. Sitaram, H.M. Bonnerjee-van der Stok, M.A. de Rie, L. Hooft, and P.I. Spuls Drug survival is not significantly different between biologics in patients with psoriasis vulgaris: a single-center database analysis Br J Dermatol 171 4 2014 875 883
14. R.B. Warren, C.H. Smith, Z.Z. Yiu, and et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR) J Invest Dermatol 135 11 2015 2632 2640
15. European Medicines Agency Committee for Medicinal Products for Human Use. Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis. CHMP/EWP/2454/02 corr. (2004, November 18). Available from: URL: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003329.pdf. Accessed January 2015.